{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:04:40Z","timestamp":1762459480484},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T00:00:00Z","timestamp":1496793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Lessons Learned<\/jats:title>\n                  <jats:p>Cobimetinib and duligotuzumab were well tolerated as single agents and in combination with other agents. The cobimetinib and duligotuzumab combination was associated with increased toxicity, most notably gastrointestinal, and limited efficacy in the patient population tested.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>KRAS-mutant tumors possess abnormal mitogen-activated protein kinases (MAPK) pathway signaling, leading to dysregulated cell proliferation. Cobimetinib blocks MAPK signaling. The dual-action antibody duligotuzumab (MEHD7945A) inhibits ligand binding to both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). Blockade of EGFR\/HER3 and inhibition of mitogen-activated protein kinase (MEK) in KRAS-mutant tumors may provide additive benefit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with KRAS-mutant solid tumors were eligible for this phase Ib dose-escalation study with a planned expansion phase. Duligotuzumab was given intravenously (IV) at 1,100 mg every 2 weeks (q2w), while cobimetinib was given orally in a standard 3\u2009+\u20093 design to identify the recommended phase II dose (RP2D). The primary objective was to evaluate the safety and tolerability of this combination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-three patients were enrolled. Dose-limiting toxicities (DLTs) included grade 4 hypokalemia and grade 3 mucosal inflammation, asthenia, and dermatitis acneiform. Seventy percent of patients experienced grade 3 or worse adverse events (AEs). Five (22%) and 12 (52%) patients missed at least 1 dose of duligotuzumab and cobimetinib, respectively, and 9 (39%) patients required a cobimetinib dose reduction. Three (13%) patients discontinued due to an AE. Best response was limited to 9 patients with stable disease and 13 patients with progressive disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Given the limited tolerability and efficacy of this combination, the study did not proceed to expansion stage and closed for enrollment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0175","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:25:45Z","timestamp":1496881545000},"page":"1024-e89","source":"Crossref","is-referenced-by-count":26,"title":["A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS"],"prefix":"10.1093","volume":"22","author":[{"given":"Christopher H.","family":"Lieu","sequence":"first","affiliation":[{"name":"Division of Medical Oncology University of Colorado Health Sciences Center, Aurora, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Hidalgo","sequence":"additional","affiliation":[{"name":"START Madrid, Centro Integral Oncologico Clara Campal (CIOCC), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan D.","family":"Berlin","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew H.","family":"Ko","sequence":"additional","affiliation":[{"name":"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Cervantes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Biomedical Research Institute INCLIVA, CIBERONC, University of Valencia, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Center, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Gerber","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Paul","family":"Eder","sequence":"additional","affiliation":[{"name":"Yale Smilow Cancer Center, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Gail","family":"Eckhardt","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology University of Colorado Health Sciences Center, Aurora, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy V.","family":"Kapp","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Tsuhako","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"McCall","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Pirzkall","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Uyei","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[{"name":"Vall d'Hebron University Hospital and Institute of Oncology, CIBERONC, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,6,7]]},"reference":[{"key":"2021122508223867800_onco12169-bib-0001","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.molmed.2007.10.002","article-title":"The HER family and cancer: Emerging molecular mechanisms and therapeutic targets","volume":"13","author":"Sergina","year":"2007","journal-title":"Trends Mol Med"},{"key":"2021122508223867800_onco12169-bib-0002","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J Clin Invest"},{"key":"2021122508223867800_onco12169-bib-0003","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","article-title":"MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors","volume":"72","author":"Turke","year":"2012","journal-title":"Cancer Res"},{"key":"2021122508223867800_onco12169-bib-0004","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1158\/0008-5472.CAN-08-3389","article-title":"Basal subtype and MAPK\/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition","volume":"69","author":"Mirzoeva","year":"2009","journal-title":"Cancer Res"},{"key":"2021122508223867800_onco12169-bib-0005","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-10-2214","article-title":"Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells","volume":"17","author":"Diep","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122508223867800_onco12169-bib-0006","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2159-8290.CD-12-0231","article-title":"Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling","volume":"3","author":"Young","year":"2013","journal-title":"Cancer Discov"},{"key":"2021122508223867800_onco12169-bib-0007","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1038\/onc.2012.402","article-title":"Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer","volume":"32","author":"Sunaga","year":"2013","journal-title":"Oncogene"},{"key":"2021122508223867800_onco12169-bib-0008","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.celrep.2014.02.045","article-title":"Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transciptional induction of ERBB3","volume":"7","author":"Sun","year":"2014","journal-title":"Cell Rep"},{"key":"2021122508223867800_onco12169-bib-0009","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fonc.2016.00232","article-title":"Randomized phase II study of duligotuzumab (MEHD7945A) vs. cetuximab in squamous cell carcinoma of the head and neck (MEHGAN Study)","volume":"6","author":"Fayette","year":"2016","journal-title":"Front Oncol"},{"key":"2021122508223867800_onco12169-bib-0010","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/35074129","article-title":"Somatic activation of the K-ras oncogene causes early onset lung cancer in mice","volume":"410","author":"Johnson","year":"2001","journal-title":"Nature"},{"key":"2021122508223867800_onco12169-bib-0011","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ceb.2008.12.010","article-title":"ErbB receptors and signaling pathways in cancer","volume":"21","author":"Hynes","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"2021122508223867800_onco12169-bib-0012","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-4827(02)00099-X","article-title":"The ErbB receptors and their role in cancer progression","volume":"284","author":"Holbro","year":"2003","journal-title":"Exp Cell Res"},{"key":"2021122508223867800_onco12169-bib-0013","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.1038\/sj.onc.1210478","article-title":"Targeting the function of the HER2 oncogene in human cancer therapeutics","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"key":"2021122508223867800_onco12169-bib-0014","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122508223867800_onco12169-bib-0015","doi-asserted-by":"crossref","first-page":"5770","DOI":"10.1128\/MCB.15.10.5770","article-title":"The cellular response to neuregulins is governed by complex interactions of the erbB receptor family","volume":"15","author":"Riese","year":"1995","journal-title":"Mol Cell Biol"},{"key":"2021122508223867800_onco12169-bib-0016","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/j.1460-2075.1996.tb00603.x","article-title":"Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions","volume":"15","author":"Pinkas-Kramarski","year":"1996","journal-title":"EMBO J"},{"key":"2021122508223867800_onco12169-bib-0017","doi-asserted-by":"crossref","first-page":"21608","DOI":"10.1073\/pnas.0912101106","article-title":"Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3","volume":"106","author":"Jura","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122508223867800_onco12169-bib-0018","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1073\/pnas.1002753107","article-title":"ErbB3\/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation","volume":"107","author":"Shi","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122508223867800_onco12169-bib-0019","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature05474","article-title":"Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3","volume":"445","author":"Sergina","year":"2007","journal-title":"Nature"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0175","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0175","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/9\/1024\/41915936\/oncolo_22_9_1024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/22\/9\/1024\/41915936\/oncolo_22_9_1024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:23:28Z","timestamp":1640420608000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/22\/9\/1024\/6444556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,7]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,6,7]]},"published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0175","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,9,1]]},"published":{"date-parts":[[2017,6,7]]}}}